A Safety and Efficacy of CCRT With Paclitaxel/Carboplatin as Adjuvant Therapy to Post-operative Cervical Cancer Patients

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine whether post-operative concurrent chemoradiation with paclitaxel/carboplatin is effective and safe in the treatment of high risk cervical cancer patients.

• Phase: Phase 2

Details

• Lead Sponsor: Korean Gynecologic Oncology Group
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel

Criteria

Inclusion Criteria:

• Patients undertaken radical hysterectomy with diagnosis of invasive cervical cancer Ib-IIa (non-small cell type)

• Patients must have at least one of the following risk factors; pelvic lymph node involvemet, involvement of vaginal resection margin,parametrial invasion.

• Patients must have a GOG performance of 0, 1, or 2.

• Patients must have expected life span over 6 months.

Exclusion Criteria:

• Patients with peripheral neurotoxicity over grade 2 in CTC criteria.

• Patients with history of chemotherapy or radiation treatment.

• Patients with histologicallly proven or highly suspected metastasis to paraaortic lymph node.

• Patients with history of hypersensitive reaction to platinum agent.